
Fred H. Reynolds
Examiner (ID: 7053, Phone: (571)270-7214 , Office: P/1675 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1658, 1675 |
| Total Applications | 1154 |
| Issued Applications | 386 |
| Pending Applications | 176 |
| Abandoned Applications | 611 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18108063
[patent_doc_number] => 20230000943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/362131
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362131
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362131 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | Jun 28, 2021 | Abandoned |
Array
(
[id] => 18675075
[patent_doc_number] => 20230312646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => ANTIBACTERIAL PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/003421
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15797
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 637
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/003421 | ANTIBACTERIAL PEPTIDES | Jun 28, 2021 | Pending |
Array
(
[id] => 18770846
[patent_doc_number] => 20230365647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => MANNOSE RECEPTOR-DERIVED PEPTIDES FOR NEUTRALIZING PORE-FORMING TOXINS FOR THERAPEUTIC USES
[patent_app_type] => utility
[patent_app_number] => 18/013679
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/013679 | MANNOSE RECEPTOR-DERIVED PEPTIDES FOR NEUTRALIZING PORE-FORMING TOXINS FOR THERAPEUTIC USES | Jun 28, 2021 | Pending |
Array
(
[id] => 18496174
[patent_doc_number] => 20230218727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => THROMBIN C-TERMINAL PEPTIDES TO TREAT CORONA VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/001611
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15396
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001611
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001611 | THROMBIN C-TERMINAL PEPTIDES TO TREAT CORONA VIRAL INFECTIONS | Jun 24, 2021 | Abandoned |
Array
(
[id] => 20715363
[patent_doc_number] => 12630598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-19
[patent_title] => IL-10 muteins and fusion proteins thereof
[patent_app_type] => utility
[patent_app_number] => 18/001913
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 22
[patent_no_of_words] => 61631
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001913
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001913 | IL-10 muteins and fusion proteins thereof | Jun 24, 2021 | Issued |
Array
(
[id] => 17513690
[patent_doc_number] => 11292820
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-05
[patent_title] => KV1.3 blockers
[patent_app_type] => utility
[patent_app_number] => 17/356354
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18494
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356354
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356354 | KV1.3 blockers | Jun 22, 2021 | Issued |
Array
(
[id] => 18769431
[patent_doc_number] => 20230364193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => COMBINED DRUG FOR TREATING CORONARIVUS DISEASE 2019
[patent_app_type] => utility
[patent_app_number] => 18/012025
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4197
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012025
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/012025 | COMBINED DRUG FOR TREATING CORONARIVUS DISEASE 2019 | Jun 20, 2021 | Abandoned |
Array
(
[id] => 17292212
[patent_doc_number] => 20210388051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE
[patent_app_type] => utility
[patent_app_number] => 17/349578
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8868
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349578
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/349578 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | Jun 15, 2021 | Abandoned |
Array
(
[id] => 18994630
[patent_doc_number] => 11911447
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Peptide pharmaceuticals for insulin resistance
[patent_app_type] => utility
[patent_app_number] => 17/349195
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 7
[patent_no_of_words] => 33796
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 318
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349195
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/349195 | Peptide pharmaceuticals for insulin resistance | Jun 15, 2021 | Issued |
Array
(
[id] => 18725827
[patent_doc_number] => 20230340048
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => TRANSFORMING GROWTH FACTOR BETA (TGFBETA) BINDING AGENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/009506
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -123
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009506
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/009506 | TRANSFORMING GROWTH FACTOR BETA (TGFBETA) BINDING AGENTS AND USES THEREOF | Jun 10, 2021 | Pending |
Array
(
[id] => 17256826
[patent_doc_number] => 20210369811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => Integrated COVID-19 Strategies
[patent_app_type] => utility
[patent_app_number] => 17/332683
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332683
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/332683 | Integrated COVID-19 Strategies | May 26, 2021 | Abandoned |
Array
(
[id] => 18449594
[patent_doc_number] => 20230190870
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => Method for Treating Lysosomal Storage Diseases with Histatin Peptides
[patent_app_type] => utility
[patent_app_number] => 17/925361
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925361
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/925361 | Method for Treating Lysosomal Storage Diseases with Histatin Peptides | May 19, 2021 | Pending |
Array
(
[id] => 18657683
[patent_doc_number] => 20230303627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => PEPTIDE FOR TREATMENT OF CORONA VIRUS INFECTION DISEASE COVID-19 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/018364
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018364
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018364 | Peptide for treatment of corona virus infection disease COVID-19 and use thereof | May 10, 2021 | Issued |
Array
(
[id] => 17214498
[patent_doc_number] => 20210347835
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/313543
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39767
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313543
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313543 | Ankyrin repeat binding proteins and their uses | May 5, 2021 | Issued |
Array
(
[id] => 18093196
[patent_doc_number] => 20220411537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => BIO-NANOCOMPOUND AS AN AGENT FOR NUCLEATING AQUEOUS-BASED COMPOUNDS AND PRODUCTION METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/781255
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781255
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/781255 | BIO-NANOCOMPOUND AS AN AGENT FOR NUCLEATING AQUEOUS-BASED COMPOUNDS AND PRODUCTION METHOD THEREOF | May 4, 2021 | Pending |
Array
(
[id] => 17200094
[patent_doc_number] => 20210340189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => SARS-COV-2 N PROTEIN AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/245599
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245599
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/245599 | SARS-COV-2 N PROTEIN AND METHODS OF USE | Apr 29, 2021 | Abandoned |
Array
(
[id] => 18420150
[patent_doc_number] => 20230174611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE EFFECTS OF INFECTIONS BY CORONAVIRUSES THAT BIND THE EXTRACELLULAR DOMAIN OF THE ACE2 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/919507
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/919507 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE EFFECTS OF INFECTIONS BY CORONAVIRUSES THAT BIND THE EXTRACELLULAR DOMAIN OF THE ACE2 RECEPTOR | Apr 25, 2021 | Pending |
Array
(
[id] => 18364648
[patent_doc_number] => 20230146239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/918448
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20619
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918448
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | Apr 12, 2021 | Pending |
Array
(
[id] => 18375995
[patent_doc_number] => 20230151077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => SOLUBLE ACE2 FOR TREATMENT OF COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/917420
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917420
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/917420 | SOLUBLE ACE2 FOR TREATMENT OF COVID-19 | Apr 8, 2021 | Pending |
Array
(
[id] => 18240185
[patent_doc_number] => 20230072496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => POLYPEPTIDE COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/917799
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -93
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917799
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/917799 | POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Apr 8, 2021 | Pending |